SAPI vs SASI in the Management of Morbid Obesity

NCT07618598 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-06-03

No results posted yet for this study

Summary

Study Design A single-center cohort study combining prospective and retrospective data collection was conducted. The prospective arm enrolled consecutively admitted patients, while the retrospective arm analyzed previously recorded cases meeting identical eligibility criteria.

Study Setting and Population

The study was performed at the General Surgery Department, Faculty of Medicine, Mansoura University. It included adults aged 18-65 years with morbid obesity eligible for bariatric surgery:

* Body mass index (BMI) ≥ 35 kg/m² with obesity-related comorbidities, or
* BMI 30-34.9 kg/m² with at least one major comorbidity \[e.g., type 2 diabetes mellitus (T2DM), hypertension (HTN), obstructive sleep apnea (OSA), dyslipidemia, osteoarthritis (OA), and gastroesophageal reflux disease (GERD)\] Study Period
* Prospective: September 2021 - September 2023
* Retrospective: January 2017 - August 2021 Eligibility Criteria Included patients were American Society of Anesthesiology (ASA) class I-III and had failed structured non-surgical weight management for ≥6 months.

Exclusion criteria included endocrine obesity, prior bariatric surgery, severe psychiatric or cognitive disorders, substance abuse, pregnancy, and previous major upper abdominal surgery.

Sample Size

Sample size was calculated based on cost difference between SASI and SAPI procedures using a two-sample means formula. A clinically relevant difference of 500 USD and SD of 700 USD were assumed, yielding:

* Total of 62 patients in the entire cohort
* Adjusted for 10% attrition → 70 total patients Final allocation was approximately 2:1 single anastomosis sleeve ileal bypass (SASI) : single anastomosis plication ileal bypass (SAPI), reflecting real-world recruitment rather than randomization.

Group Allocation Non-randomized assignment was used. Prospective allocation involved shared decision-making within a multidisciplinary team, while retrospective allocation was based on prior surgical records. Influencing factors included cost, availability, insurance, and patient preference.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Methods Preoperative Assessment

Comprehensive evaluation included:

* Detailed medical history and comorbidity assessment
* Nutritional deficiency screening and correction
* Anthropometric measurements
* Laboratory tests
* Imaging (as indicated) Validated Questionnaires
* Physical activity: using The Rapid Assessment of Physical Activity (RAPA)
* Eating behavior: Self-Regulation of Eating Behavior Questionnaire (SREB-Q) and The Eating Attitudes Test (EAT-26)
* Sleep quality: The Pittsburgh Sleep Quality Index (PSQI)
* Socioeconomic status: Fahmy \& El-Sherbini scale
* Quality of life (QoL): The Moorehead-Ardelt Quality of Life Questionnaire II (MA-QoL II)

Surgical Procedures

Two laparoscopic techniques were performed:

SASI

* Sleeve gastrectomy over 36-Fr bougie
* 300 cm ileal loop anastomosed to gastric antrum
* Stapled side-to-side stapled gastroileal anastomosis SAPI
* Same, but gastric devascularization and plication over a 36-Fr bougie rather than sleeve gastrectomy Both procedures included leak testing, drain placement, and dual-outlet gastric configuration.

Postoperative Management

Standardized enhanced recovery protocol:

* Early mobilization and VTE prophylaxis
* Proton pump inhibitors and analgesia
* Gradual oral intake from postoperative day 1
* Imaging and lab assessment when indicated
* Early discharge if stable

Cost Analysis

A micro-costing approach was used, including:

* Primary costs: technology, personnel, instruments, disposables, hospitalization, follow-up, supplements
* Secondary costs: readmissions and re-interventions Cost components were calculated using standardized formulas for each item Total cost = Primary + Secondary costs

Cost-effectiveness was evaluated using:

* Cost-effectiveness ratios (CER)
* Incremental cost-effectiveness ratio (ICER)
* Outcomes included percentage of excess weight loss (%EWL), complication rates, readmission, comorbidity remission, and The Bariatric Analysis and Reporting Outcome System (BAROS).

Follow-Up and Outcomes

Follow-up included:

* Weekly (1st month), biweekly (next 2 months), then quarterly (up to 1 year)
* Assessment of weight loss, comorbidities, complications, and QoL

Primary outcome:

• Total cost difference between SASI and SAPI

Secondary outcomes:

* Operative time, length of hospital stay, complications
* %EWL, comorbidity remission
* QoL (MA-QoL II, BAROS)

Statistical Analysis

Performed using SPSS v26:

* Normality: Shapiro-Wilk test
* Continuous data: t-test or Mann-Whitney U
* Categorical data: Chi-square or Fisher's test
* Regression: linear and logistic models
* Significance set at p \< 0.05.

Conditions

  • Morbid Obesity Requiring Bariatric Surgery

Interventions

PROCEDURE

Single Anastomosis Sleeve Ileal (SASI) Bypass Procedure

Participants undergo laparoscopic SASI bariatric surgery consisting of sleeve gastrectomy followed by a single omega-loop gastroileal anastomosis. An isoperistaltic ileal limb is measured 300 cm proximal to the ileocecal valve. A stapled side-to-side gastroileal anastomosis is created, and the staple entry site is closed with barbed sutures. Standard leak testing and drain placement are performed.

PROCEDURE

Single Anastomosis Plication Ileal (SAPI) Bypass Procedure

Participants undergo laparoscopic SAPI bariatric surgery involving gastric plication followed by a single omega-loop gastroileal anastomosis. An isoperistaltic ileal limb is measured 300 cm from the ileocecal valve. A stapled side-to-side anastomosis is performed between the gastric antrum and ileal loop, with closure of the enterotomy using barbed sutures. Leak testing and drain placement are routinely performed.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-11
Primary Completion
2024-07-11
Completion
2025-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07618598 on ClinicalTrials.gov